The World Health Organization said on Monday it had approved the Bavarian Nordic mpox vaccine for teenagers aged 12 to 17, an age group considered particularly at risk of an outbreak of the disease that has raised global concerns.
The WHO said in a statement that it granted pre-certification to the Jynneos vaccine for teenagers on October 8.
In August, the WHO declared mpox as a global public health emergency for the second time in two years, after a new strain of the virus spread from the Democratic Republic of Congo to its neighbors.
The United Nations agency approved the use of the vaccine as the first mpox vaccine in adults in September, making the vaccine available in the most affected African countries.
Children, teenagers and people with weakened immune systems are particularly at risk of mpox, a viral infection that often causes flu-like symptoms and pus-filled skin sores.
The latest decision by the WHO comes after the EU approved the vaccine drug for teenagers in September.
2024-10-14 06:51:00
#approves #Bavarian #Nordic #mpox #vaccine #adolescents
